Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when VIR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: VIR Vir Biotechnology, Inc. 8-K

Vir Biotechnology Audit Committee Chair Ramasastry resigns over business conflict

Filed May 28, 2026 · Period ending May 25, 2026 · ~1 min read

3 key changes 1 section

Key Changes

  • medium

    Audit Committee Chair Saira Ramasastry resigned from the Board effective May 26, 2026, citing a business conflict. The company stated her departure was not due to any disagreement on operations, policies, or practices.

  • medium

    Robert More was immediately appointed as new Audit Committee Chair following Ramasastry's departure. The Board reduced its size from eight to seven members with no immediate replacement planned.

  • low

    At the 2026 Annual Meeting, stockholders elected three Class I directors (More, Napolitano, Sigal) to serve until 2029, approved executive compensation on an advisory basis, and ratified Ernst & Young as auditor.

Summary

Vir Biotechnology experienced a sudden change in its Audit Committee leadership when Chair Saira Ramasastry resigned on May 25, 2026, effective the next day, citing a business conflict. The company emphasized that her departure was not related to any disagreement with management or company practices.

Robert More, who was simultaneously re-elected as a Class I director at the annual meeting, was immediately appointed to replace her as Audit Committee Chair. For retail investors, the abrupt nature of the resignation and the vague 'business conflict' explanation warrant attention, though the company's explicit statement about no disagreements provides some reassurance.

The Board's decision to shrink from eight to seven members rather than seek a replacement suggests confidence in the current composition. More's dual role as both a director and Audit Committee Chair indicates continuity in financial oversight. Investors should monitor the next quarterly earnings call and any subsequent SEC filings for additional context about the business conflict and whether it relates to any potential issues with Vir's operations or financial reporting. The company's financial controls and audit processes should remain stable under More's leadership.

Section-by-Section Diff

Event · Item 5.07 — Submission of Matters to a Vote of Security Holders

~400 words

Item 5.07 — Submission of Matters to a Vote of Security Holders filed; see Key Changes for terms.

3 Added
Show 3 minor / wording changes
Added Director elections low

Added in current filing · verify on EDGAR →

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal.

Three Class I directors were elected at the 2026 Annual Meeting: Robert More, Janet Napolitano, and Elliott Sigal. Each will serve a three-year term until 2029. All three received majority support, with Robert More receiving 114,856,835 votes for, Janet Napolitano receiving 67,235,175 votes for, and Elliott Sigal receiving 115,030,681 votes for.

Added Executive compensation advisory vote low

Added in current filing · verify on EDGAR →

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.

Stockholders approved executive compensation on an advisory basis with 108,453,963 votes for, 11,863,405 votes against, and 1,372,563 abstentions. This non-binding say-on-pay vote indicates shareholder support for the company's executive compensation practices.

Added Auditor ratification low

Added in current filing · verify on EDGAR →

The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Stockholders ratified Ernst & Young LLP as the independent auditor for fiscal year 2026 with overwhelming support: 137,048,756 votes for, 153,836 votes against, and 1,164,682 abstentions. This is a routine annual approval of the audit firm.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify